Subscribe To

Price Alert Latest News Economic Calendar News

AMED / Amedisys received unsolicited buyout bid from Optum that could be ‘superior' to deal with Option Care Health

Amedisys Inc. AMED, +3.64% disclosed Monday that it had received an unsolicited cash buyout bid for $100 a share from Optum, which the at-home healthcare services company believes could be considered “superior” to the buyout deal already agreed on with Option Care Health Inc. OPCH, +2.99% in early May. Amedisys shares were still inactive in premarket trading while Option Care's stock rallied 4.7%. Read More

Demo Live Account See Partner Details

Content Topics

Amedisys

Received

Unsolicited

Buyout

From

Optum

That

Could

superior

Option

Health

Stock

AMED

Posted: Jun 5 2023, 08:39

Author Name: Market Watch

AMED News

By Seeking Alpha
November 3, 2023

Amedisys, Inc.: Why Stock Is A Hold Pending Agency Review

Amedisys, Inc. is set to be acquired by UnitedHealth Group in a $3.29 billion merger agreement. Some US legislators have called for further scrutiny o

By Zacks Investment Research
October 24, 2023

Amedisys (AMED) Reports Q3 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Amedisys (AMED) give a sense of how its business performed in the quarter ended September 2023, it might be worth con

By Zacks Investment Research
October 24, 2023

Amedisys (AMED) Q3 Earnings and Revenues Lag Estimates

Amedisys (AMED) came out with quarterly earnings of $0.98 per share, missing the Zacks Consensus Estimate of $1.08 per share. This compares to earning

By Zacks Investment Research
October 18, 2023

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

Here is how Amedisys (AMED) and Cybin Inc. (CYBN) have performed compared to their sector so far this year.

By Zacks Investment Research
July 28, 2023

Amedisys (AMED) Q2 Earnings Beat Estimates, Margins Dip

Strength in Hugh Acuity Care segment and Hospice division drive Amedisys (AMED) Q2 performance.

By Zacks Investment Research
July 26, 2023

Amedisys (AMED) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Amedisys (AMED) give a sense of how the business performed in the quarter ended June 2023, it could be wort

By PYMNTS
June 26, 2023

UnitedHealth's Amedisys Deal Come as Home Health and Data Cement Care Ecosystems

In healthcare, the latest acquisition brings to mind that old Fred Astaire song lyric: “Won't you change partners and dance with me?” On Monday,

By Investopedia
June 26, 2023

UnitedHealth Buys Amedisys for $3.3 Billion

UnitedHealth Group outbid Option Care's offer to buy home healthcare provider Amedisys.

Risk Disclosure:

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
We would like to remind you that the data contained in this website is not necessarily real-time nor accurate.
The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. We and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of us and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. We may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.